{
    "2019-08-27": [
        [
            {
                "time": "2018-09-15",
                "original_text": "Should You Buy AbbVie for the Dividend?",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Dividend"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-04-23",
                "original_text": "Lilly's (LLY) Taltz Gets FDA Nod for Ankylosing Spondylitis",
                "features": {
                    "keywords": [
                        "Lilly",
                        "Taltz",
                        "FDA",
                        "Ankylosing Spondylitis"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2019-11-12",
                "original_text": "Amgen to Buy Celgene's Otezla for $13.4B: Is it a Good Buy?",
                "features": {
                    "keywords": [
                        "Amgen",
                        "Celgene",
                        "Otezla",
                        "Acquisition"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-09-10",
                "original_text": "AbbVie to Present at the Morgan Stanley Healthcare Conference",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Morgan Stanley",
                        "Healthcare Conference"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-08-20",
                "original_text": "Why Jim Cramer's Negative Take on Pfizer Is Flat-Out Wrong",
                "features": {
                    "keywords": [
                        "Jim Cramer",
                        "Pfizer",
                        "Negative Take"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2019-07-15",
                "original_text": "This dividend-stock strategy is for investors who want an attractive monthly income stream",
                "features": {
                    "keywords": [
                        "dividend-stock",
                        "strategy",
                        "monthly income"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "finance"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-08-20",
                "original_text": "Why Jim Cramer's Negative Take on Pfizer Is Flat-Out Wrong",
                "features": {
                    "keywords": [
                        "Jim Cramer",
                        "Pfizer",
                        "Negative Take"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}